ArticleBreast cancer research : BCR2025
The aetiology of breast cancer subtypes: results from the Million Women Study.
Article in Breast cancer research : BCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundEvidence regarding the aetiology of specific breast cancer subtypes may provide insights into the mechanisms underlying their development, and improve prevention of rarer but more aggressive subtypes. We investigated risk factor associations with surrogate molecular subtypes of breast cancer in a large cohort of UK women.
methodsIn 1.2 million postmenopausal women aged 50-64 recruited into the Million Women Study in 1996-2001, we estimated risks of breast cancer subtypes (defined by oestrogen receptor [ER], progesterone receptor [PR], and human epidermal growth factor receptor 2 [HER2] status) in relation to established risk factors for breast cancer.
resultsAmong 1,228,671 eligible women, followed on average for 19.8 (SD 6.5) years, there were 58,134 incident breast cancers with known ER status and 40,627 with known surrogate molecular subtype (based on ER, PR, and HER2 status). Most established risk factors were primarily either positively (age at first birth, age at menopause, BMI, height, alcohol intake, and menopausal hormone therapy use) or inversely (parity) associated with ER+ cancer (p-value for heterogeneity by ER status < = 0.002 in each case). Only prior oral contraceptive (OC) use showed a greater association with ER than with ER+ cancer (p = 0.002). Some additional differences were observed by surrogate molecular subtype including a modest positive association of parity, and inverse association of breastfeeding, with the risk of basal-like cancer.
conclusionsMost established risk factors for breast cancer are almost exclusively associated with hormone-sensitive cancers but some have definite associations with ER- cancers (prior OC use), or more specifically, with basal-like cancer (parity, breastfeeding).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.